
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is a pioneer in precision medicine utilizing their Dynamo platform to target previously intractable diseases such as breast cancer and genetic disorders. With a strong financial position and multiple ongoing development programs, the company is well-positioned to drive future growth and deliver value to patients and investors alike. While clinical trials inherently carry risks, strong preliminary data and potential regulatory approvals for their lead drug candidates, as well as a relatively limited competitive landscape, make Relay Therapeutics a promising investment opportunity.
Bears say
Relay Therapeutics is a precision medicine company with a focus on developing therapies for precision oncology and genetic diseases. However, their financials do not support the potential risks associated with investing in a clinical-stage company, such as limited cash and significant operating expenses. Additionally, there is concern among key opinion leaders about the potential for growth impairment with their lead product candidate compared to competitors in the same space.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares